Barclays PLC Grows Position in Emergent BioSolutions Inc. (NYSE:EBS)

Barclays PLC raised its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 361.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,308 shares of the biopharmaceutical company’s stock after acquiring an additional 30,792 shares during the period. Barclays PLC’s holdings in Emergent BioSolutions were worth $329,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC bought a new stake in Emergent BioSolutions in the second quarter worth $93,000. Stifel Financial Corp purchased a new stake in shares of Emergent BioSolutions during the 3rd quarter valued at about $96,000. Morse Asset Management Inc purchased a new stake in shares of Emergent BioSolutions during the 2nd quarter valued at about $97,000. FORA Capital LLC purchased a new position in Emergent BioSolutions in the third quarter worth about $103,000. Finally, Landscape Capital Management L.L.C. bought a new stake in Emergent BioSolutions during the third quarter worth approximately $141,000. 78.40% of the stock is currently owned by institutional investors.

Emergent BioSolutions Trading Down 0.7 %

Shares of NYSE EBS opened at $9.91 on Monday. Emergent BioSolutions Inc. has a fifty-two week low of $1.42 and a fifty-two week high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company has a market cap of $536.69 million, a price-to-earnings ratio of -2.42 and a beta of 1.60. The business’s 50 day moving average price is $9.31 and its 200-day moving average price is $9.23.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on EBS. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research note on Friday, January 10th. StockNews.com raised shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Benchmark increased their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.